{"id":"mgd","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL4298038","moleculeType":"Unknown"},"_dailymed":{"setId":"06f57d46-96c7-4093-84aa-874ff4b2131d","title":"RETAINE MGD (MINERAL OIL) EMULSION [OCUSOFT LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MGd irreversibly binds to BTK, a key enzyme in B-cell receptor signaling, preventing downstream activation of survival and proliferation pathways. This mechanism is particularly effective in B-cell malignancies where BTK signaling is critical for tumor cell survival. The drug has demonstrated clinical activity in chronic lymphocytic leukemia and other lymphoid malignancies.","oneSentence":"MGd is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells to reduce proliferation and survival of malignant cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:56.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"}]},"trialDetails":[{"nctId":"NCT05577910","phase":"NA","title":"Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2022-10-08","conditions":"Meibomian Gland Dysfunction","enrollment":374},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT07457021","phase":"","title":"A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Ophthalmology Center Affiliated to Xiamen University","startDate":"2026-03-01","conditions":"Dry Eye Disease","enrollment":2000},{"nctId":"NCT07415330","phase":"NA","title":"Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Demaod Ltd","startDate":"2026-02-20","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":20},{"nctId":"NCT07365735","phase":"NA","title":"A Prospective, Randomized, Controlled Trial of the TearCare MGX™ System With and Without Warming Hold","status":"NOT_YET_RECRUITING","sponsor":"Sight Sciences, Inc.","startDate":"2026-02","conditions":"Meibomian Gland Dysfunction (Disorder)","enrollment":20},{"nctId":"NCT07329712","phase":"","title":"Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy","status":"RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-11-05","conditions":"Dry Eye, Meibomian Gland Dysfunction (Disorder)","enrollment":30},{"nctId":"NCT07229001","phase":"NA","title":"Treating Meibomian Gland Disease in a Pediatric Population","status":"ENROLLING_BY_INVITATION","sponsor":"Illinois College of Optometry","startDate":"2024-10-01","conditions":"Dry Eye Disease, Meibomian Gland Disease","enrollment":15},{"nctId":"NCT05454956","phase":"PHASE2","title":"Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2022-08-03","conditions":"Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation","enrollment":39},{"nctId":"NCT07169461","phase":"NA","title":"Effectiveness of Low Level Light Therapy and Intense Pulse Light on Mite Count as Adjuntive Therapies in Demodex Blepharitis Using Artificial Intelligent Program (Ai-Demodex)","status":"ENROLLING_BY_INVITATION","sponsor":"Chulalongkorn University","startDate":"2025-01-16","conditions":"Demodex Blepharitis, Meibomian Gland Dysfunction (MGD)","enrollment":88},{"nctId":"NCT06064071","phase":"NA","title":"Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candela Corporation","startDate":"2023-09-18","conditions":"Meibomian Gland Dysfunction, Dry Eye Disease","enrollment":100},{"nctId":"NCT03767530","phase":"NA","title":"Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2019-09-01","conditions":"Meibomian Gland Dysfunction","enrollment":42},{"nctId":"NCT01207752","phase":"NA","title":"The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2010-09","conditions":"Meibomian Gland Dysfunction","enrollment":69},{"nctId":"NCT06220474","phase":"NA","title":"Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-10-22","conditions":"Dry Eye Syndromes, Meibomian Gland Dysfunction","enrollment":112},{"nctId":"NCT06686368","phase":"PHASE4","title":"Comparative Efficacy Study to Demonstrate the Non-inferiority of I-DROP® MGD Versus 2 Competitor Eye Drops in Managing Evaporative Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"I-MED Pharma","startDate":"2024-11-15","conditions":"Evaporative Dry Eye Disease","enrollment":60},{"nctId":"NCT06542276","phase":"NA","title":"Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED","status":"ENROLLING_BY_INVITATION","sponsor":"Dunes Eye Consultants","startDate":"2023-09-01","conditions":"MGD-Meibomian Gland Dysfunction","enrollment":30},{"nctId":"NCT06525961","phase":"PHASE4","title":"iTear Single-center, Open-label, Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-08","conditions":"Dry Eye Disease, Dry Eye Syndromes, Dry Eye","enrollment":30},{"nctId":"NCT05261386","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2022-03-04","conditions":"Meibomian Gland Dysfunction","enrollment":95},{"nctId":"NCT05159284","phase":"PHASE4","title":"Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction","status":"RECRUITING","sponsor":"Laboratorios Thea, Spain","startDate":"2021-11-09","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":54},{"nctId":"NCT03652051","phase":"PHASE2","title":"A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Azura Ophthalmics","startDate":"2018-09-10","conditions":"Meibomian Gland Dysfunction, Dry Eye","enrollment":321},{"nctId":"NCT06242860","phase":"NA","title":"Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease","status":"COMPLETED","sponsor":"Eyedetec Medical, Inc.","startDate":"2022-02-08","conditions":"Evaporative Dry Eye Disease, Meibomian Gland Dysfunction","enrollment":31},{"nctId":"NCT05306561","phase":"NA","title":"Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users","status":"UNKNOWN","sponsor":"Periman Eye Institute","startDate":"2022-01-26","conditions":"Meibomian Gland Dysfunction, Dry Eye","enrollment":30},{"nctId":"NCT06119386","phase":"NA","title":"Quantum Molecular Resonance Electrotherapy in Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Centro Oculistico Borroni","startDate":"2022-11-03","conditions":"Dry Eye","enrollment":81},{"nctId":"NCT06034626","phase":"PHASE3","title":"Therapeutic Effectiveness of Different Machines in Intense Pulsed Light Treatment of Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-11-03","conditions":"MGD-Meibomian Gland Dysfunction","enrollment":216},{"nctId":"NCT04052841","phase":"NA","title":"Morphological Analysis of Meibomian Glands","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2020-10-12","conditions":"Meibomian Gland Dysfunction","enrollment":180},{"nctId":"NCT05771194","phase":"PHASE4","title":"Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2021-02-01","conditions":"Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid","enrollment":40},{"nctId":"NCT05383612","phase":"NA","title":"To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2022-08-05","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":140},{"nctId":"NCT05553561","phase":"NA","title":"Intense Regulated Pulse Light Therapy in Dry Eye Disease","status":"UNKNOWN","sponsor":"Menoufia University","startDate":"2023-01-01","conditions":"Dry Eye Disease","enrollment":34},{"nctId":"NCT03972501","phase":"PHASE2","title":"An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)","status":"COMPLETED","sponsor":"Azura Ophthalmics","startDate":"2019-10-04","conditions":"Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)","enrollment":26},{"nctId":"NCT04314362","phase":"PHASE2, PHASE3","title":"Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)","status":"COMPLETED","sponsor":"Azura Ophthalmics","startDate":"2020-07-14","conditions":"Meibomian Gland Dysfunction","enrollment":32},{"nctId":"NCT05487547","phase":"NA","title":"Feasibility of IPL Combined With RF for Treatment of DED Due to MGD","status":"COMPLETED","sponsor":"Lumenis Be Ltd.","startDate":"2022-07-21","conditions":"Dry Eye Disease, Meibomian Gland Dysfunction","enrollment":33},{"nctId":"NCT05512572","phase":"NA","title":"Therapeutic Efficacy of Intense Pulsed Light in the Treatment of Chalazion","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08-23","conditions":"Chalazion","enrollment":80},{"nctId":"NCT04658927","phase":"PHASE4","title":"Dextenza With ILUX for Treatment of MGD","status":"COMPLETED","sponsor":"Warrenville Eyecare","startDate":"2021-01-04","conditions":"Meibomian Gland Dysfunction, Evaporative Dry Eye","enrollment":30},{"nctId":"NCT03968731","phase":"NA","title":"Meibomian Gland Dysfunction Management With ZEST Protocol","status":"COMPLETED","sponsor":"University of the Incarnate Word","startDate":"2019-06-10","conditions":"Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease","enrollment":30},{"nctId":"NCT04391959","phase":"PHASE2","title":"Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)","status":"COMPLETED","sponsor":"Azura Ophthalmics","startDate":"2020-07-17","conditions":"Meibomian Gland Dysfunction","enrollment":31},{"nctId":"NCT02958514","phase":"NA","title":"Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2016-11","conditions":"Dry Eye Syndrome","enrollment":20},{"nctId":"NCT05331924","phase":"NA","title":"Quality of Life Improvement in Dry Eye Patients After Intense Pulsed Light Therapy Compared to Punctal Plugs","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-12-01","conditions":"Evaporative Dry Eye","enrollment":30},{"nctId":"NCT04413279","phase":"PHASE4","title":"Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Eye Surgeons of Indiana","startDate":"2020-08-01","conditions":"Dry Eye Syndromes","enrollment":20},{"nctId":"NCT05011708","phase":"NA","title":"I-DROP MGD Symptomatic Relief and Tear Film Stability","status":"COMPLETED","sponsor":"I-MED Pharma","startDate":"2021-08-23","conditions":"Dry Eye","enrollment":10},{"nctId":"NCT04500821","phase":"NA","title":"Evaluation of the LipiFlow System With a New Activator","status":"COMPLETED","sponsor":"Johnson & Johnson Surgical Vision, Inc.","startDate":"2020-10-02","conditions":"Meibomian Gland Dysfunction","enrollment":44},{"nctId":"NCT03956225","phase":"NA","title":"Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2019-06-25","conditions":"Meibomian Gland Dysfunction, Evaporative Dry Eye Disease","enrollment":299},{"nctId":"NCT01549886","phase":"PHASE2","title":"Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2011-11","conditions":"Non-Hodgkin's Lymphoma","enrollment":5},{"nctId":"NCT04962386","phase":"","title":"Clinical Efficacy of Hormone Replacement Therapy in Treating Perimenopausal Women With MGD","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2019-03-06","conditions":"Meibomian Gland Dysfunction","enrollment":30},{"nctId":"NCT05028491","phase":"","title":"The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients","status":"COMPLETED","sponsor":"Wenzhou Medical University","startDate":"2020-10-01","conditions":"Meibomian Gland Dysfunction","enrollment":62},{"nctId":"NCT03888378","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Hovione Scientia Limited","startDate":"2019-04-02","conditions":"Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction","enrollment":270},{"nctId":"NCT04633798","phase":"NA","title":"Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction","status":"UNKNOWN","sponsor":"Aier School of Ophthalmology, Central South University","startDate":"2020-12-01","conditions":"Meibomian Gland Dysfunction","enrollment":100},{"nctId":"NCT03055650","phase":"NA","title":"iLux Treatment for Meibomian Gland Dysfunction (MGD)","status":"COMPLETED","sponsor":"Tear Film Innovations, Inc.","startDate":"2015-12-07","conditions":"Evaporative Dry Eye","enrollment":30},{"nctId":"NCT04608942","phase":"NA","title":"Refractory Meibomian Gland Dysfunction and Plasma Jet","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2019-11-11","conditions":"Meibomian Gland Dysfunction, Dry Eye Disease, Evaporative Dry Eye","enrollment":25},{"nctId":"NCT03788486","phase":"NA","title":"Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device","status":"WITHDRAWN","sponsor":"Toyos Clinic","startDate":"2019-02-12","conditions":"Meibomian Gland Dysfunction","enrollment":""},{"nctId":"NCT03265652","phase":"NA","title":"IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD","status":"COMPLETED","sponsor":"Lumenis Be Ltd.","startDate":"2018-05-15","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":24},{"nctId":"NCT02975557","phase":"PHASE1, PHASE2","title":"Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)","status":"TERMINATED","sponsor":"Sandeep Jain, MD","startDate":"2016-05","conditions":"Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction","enrollment":15},{"nctId":"NCT00089284","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-10-28","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":30},{"nctId":"NCT03492541","phase":"NA","title":"Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2018-07-18","conditions":"Dry Eye Disease","enrollment":134},{"nctId":"NCT01808560","phase":"NA","title":"Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery","status":"COMPLETED","sponsor":"TearScience, Inc.","startDate":"2013-03","conditions":"Blepharitis, Dry Eye Syndrome","enrollment":34},{"nctId":"NCT03515187","phase":"PHASE3","title":"Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma Drops","status":"UNKNOWN","sponsor":"Shenzhen Hospital of Southern Medical University","startDate":"2018-06","conditions":"Dry Eye, MGD-Meibomian Gland Dysfunction","enrollment":160},{"nctId":"NCT00305864","phase":"PHASE1, PHASE2","title":"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-02-09","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":118},{"nctId":"NCT03337295","phase":"","title":"The Correlation Between the Thickness of Lipid Layer and the Meibomian Gland Dysfunction","status":"UNKNOWN","sponsor":"Wenzhou Medical University","startDate":"2016-01","conditions":"Meibomian Gland Dysfunction","enrollment":100},{"nctId":"NCT01456780","phase":"PHASE4","title":"Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-08","conditions":"Meibomian Gland Dysfunction, Posterior Blepharitis","enrollment":60},{"nctId":"NCT03061578","phase":"","title":"Evaluation of Dry Eye by Tear Film Imager in a Low Humidity Environmental Exposure Chamber (TFI-LH16)","status":"COMPLETED","sponsor":"Adom Advanced Optical Technologies Ltd.","startDate":"2017-01-26","conditions":"Dry Eye","enrollment":29},{"nctId":"NCT02621593","phase":"NA","title":"Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD","status":"COMPLETED","sponsor":"Lumenis Be Ltd.","startDate":"2015-10","conditions":"Dry Eye Syndromes","enrollment":44},{"nctId":"NCT02411487","phase":"","title":"Meibomian Gland Dysfunction (MGD) and Tear Cytokines After Cataract Surgery According to Preoperative Meibomian Gland Status","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-03-16","conditions":"Cataract","enrollment":50},{"nctId":"NCT02992535","phase":"PHASE4","title":"Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity","status":"UNKNOWN","sponsor":"Carones Ophthalmology Center","startDate":"2017-01","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT02943382","phase":"NA","title":"Fingerprick Autologous Blood (FAB) in Mebomian Gland Dysfunction (MGD)","status":"UNKNOWN","sponsor":"Bedford Hospital NHS Trust","startDate":"2016-11","conditions":"Meibomian Gland Dysfunction, Dry Eye Disease","enrollment":20},{"nctId":"NCT01228929","phase":"NA","title":"Non-invasive Ocular Surface Measurements Before and After Interventions","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2010-07","conditions":"Dry Eye Syndrome, Healthy","enrollment":18},{"nctId":"NCT01552174","phase":"","title":"Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2012-03","conditions":"Palpebral Pathologies, Ocular Surface Disease, Meibomian Gland Dysfunction","enrollment":185},{"nctId":"NCT01128049","phase":"NA","title":"Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-06","conditions":"Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction","enrollment":15},{"nctId":"NCT01521507","phase":"NA","title":"Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye","status":"COMPLETED","sponsor":"TearScience, Inc.","startDate":"2012-01","conditions":"Meibomian Gland Dysfunction, Dry Eye","enrollment":200},{"nctId":"NCT01979887","phase":"","title":"Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-11","conditions":"Meibomian Glands","enrollment":75},{"nctId":"NCT00373204","phase":"PHASE2","title":"Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)","status":"TERMINATED","sponsor":"Pharmacyclics LLC.","startDate":"2006-05","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT00076401","phase":"PHASE2","title":"A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"Pharmacyclics LLC.","startDate":"","conditions":"Leukemia, Leukemia, Lymphocytic, Chronic","enrollment":27},{"nctId":"NCT00100711","phase":"PHASE2","title":"Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"Pharmacyclics LLC.","startDate":"2004-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT01692652","phase":"NA","title":"Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)","enrollment":98},{"nctId":"NCT00003563","phase":"PHASE3","title":"Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"1998-08","conditions":"Metastatic Cancer","enrollment":430},{"nctId":"NCT00365183","phase":"PHASE2","title":"Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Pharmacyclics LLC.","startDate":"2006-06","conditions":"Non-Small Cell Lung Carcinoma","enrollment":74},{"nctId":"NCT00734773","phase":"EARLY_PHASE1","title":"Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-11","conditions":"Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity","enrollment":""},{"nctId":"NCT00120939","phase":"PHASE1","title":"Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"","conditions":"Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms","enrollment":25},{"nctId":"NCT00080054","phase":"PHASE1","title":"A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"","conditions":"Glioma, Glioblastoma, Astrocytoma","enrollment":24},{"nctId":"NCT00102505","phase":"PHASE1","title":"A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2004-11","conditions":"Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic","enrollment":36},{"nctId":"NCT00290004","phase":"PHASE1, PHASE2","title":"Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2005-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia","enrollment":35},{"nctId":"NCT00129844","phase":"PHASE2","title":"Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2005-09","conditions":"Adenocarcinoma, Non-Small-Cell Lung Carcinoma, Lung Neoplasms","enrollment":108},{"nctId":"NCT00086034","phase":"PHASE2","title":"Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"","conditions":"Lymphoma, Non-Hodgkin's Lymphoma","enrollment":35},{"nctId":"NCT00080041","phase":"PHASE1","title":"Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"","conditions":"Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms","enrollment":20},{"nctId":"NCT00096837","phase":"PHASE2","title":"A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"","conditions":"Multiple Myeloma","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19523,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MGd plus WBRT"],"phase":"marketed","status":"active","brandName":"MGd","genericName":"MGd","companyName":"Pharmacyclics LLC.","companyId":"pharmacyclics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MGd is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells to reduce proliferation and survival of malignant cells. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}